Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1546247 | 0.81 | — | — | |
| SCHEMBL863172 | 0.78 | — | — | |
| SCHEMBL5892413 | 0.78 | — | — | |
| SCHEMBL275007 | 0.78 | ALDH1A1 (0.31) | ALDH1A1CYP2C9HPGDHSD17B10 | |
| SCHEMBL610247 | 0.78 | ALDH1A1 (0.31) | ALDH1A1CYP2C9HPGDHSD17B10 | |
| SCHEMBL2002515 | 0.78 | — | — | |
| SCHEMBL17263960 | 0.76 | MEN1 (0.33) | — | |
| SCHEMBL13858441 | 0.76 | PIK3CD (0.31) | — | |
| SCHEMBL31066753 | 0.70 | ALDH1A1 (0.32) | ALDH1A1CYP2C9HPGDHSD17B10 | |
| SCHEMBL25862136 | 0.70 | ALDH1A1 (0.32) | ALDH1A1CYP2C9HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772313-B2 | Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-HT6 receptor | ABBOTT LABORATORIES (US) | 2014-07-08 | — | — | US | disclosed |
| US-8691865-B2 | Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers | ABBVIE INC. (US) | 2014-04-08 | — | — | US | disclosed |
| US-8470810-B2 | Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-06-25 | — | — | US | disclosed |
| US-20120129883-A1 | BENZENESULFONYL OR SULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OFTHE SEROTONIN 5-HT6 RECEPTOR | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | US | disclosed |
| US-8129417-B2 | Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers | ABBOTT LABORATORIES (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110160176-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2011-06-30 | — | — | US | disclosed |
| US-7847117-B2 | Process for preparing alkyl(methoxymethyl)trimethylsilanylmethylamines | WACKER CHEMIE AG (DE) | 2010-12-07 | — | — | US | disclosed |
| EP-2050754-B1 | Method for manufacturing alkyl-methoxymethyl-trimethylsilanylmethyl amines | WACKER CHEMIE AG (DE) | 2010-09-15 | — | — | EP | disclosed |
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-05-27 | — | — | US | disclosed |
| EP-2050754-A1 | Method for manufacturing alkyl-methoxymethyl-trimethylsilanylmethyl amines | Wacker Chemie AG (DE) | 2009-04-22 | — | — | EP | disclosed |
| US-20090036700-A1 | Process For Preparing Alkyl(Methoxymethyl)Trimethylsilanylmethylamines | WACKER CHEMIE AG (DE) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129883-A1 | BENZENESULFONYL OR SULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OFTHE SEROTONIN 5-HT6 RECEPTOR | HTR6, HTR2A, HTR2B | ALDH1A1 997/4885CYP2C9 297/4885HPGD 1134/4885 |
| US-20090036700-A1 | Process For Preparing Alkyl(Methoxymethyl)Trimethylsilanylmethylamines | PNMT, TET2, HNMT | ALDH1A1 3385/4885CYP2C9 2343/4885HPGD 4428/4885 |
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | ALDH1A1 556/4885CYP2C9 1203/4885HPGD 1353/4885 |
| US-20110160176-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | DRD3, CHRNA3, CHRM3 | ALDH1A1 1372/4885CYP2C9 1410/4885HPGD 1794/4885 |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | ALDH1A1 556/4885CYP2C9 1203/4885HPGD 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.